Treatment Revolution: The New Era Against Hepatitis C

1 Mihalache L, Graur LI, Popescu DS, Boiculese L, Badiu C, Graur M. The prevalence of the metabolic syndrome and its components in a rural community. Acta Endocrinologica (Buc). 2012; 8(4): 595-606. Search in Google Scholar

2 Hurjui DM, Niţă O, Graur LI, Mihalache L, Popescu DS, Huţanaşu IC, Ungureanu D, Graur M. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Rev Med Chir Soc Med Nat Iasi. 2012 Jul-Sep;116(3):692-9. Search in Google Scholar

3 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362. Search in Google Scholar

4 Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982. Search in Google Scholar

5 Messina JP, Humphreys I, Flaxman A et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87. Search in Google Scholar

6 Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134. Search in Google Scholar

7 McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492. Search in Google Scholar

8 Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206. Search in Google Scholar

9 Manns MP, Buti M, Gane E et al. Hepatitis C virus infection. Nar Rec Dis Primers 2017; 3: 17006. Search in Google Scholar

10 Hurjui DM, Niţă O, Graur LI, Mihalache L, Popescu DS, Graur M. The central role of the non alcoholic fatty liver disease in metabolic syndrome. Rev Med Chir Soc Med Nat Iasi. 2012 Apr-Jun;116(2):425-31. Search in Google Scholar

11 Kronfli N, Young J, Wang S et al; Canadian Co-infection Cohort Study Investigators. Liver fibrosis in HIV-hepatitis C virus (HCV) co-infection before and after sustained virologic response: what is the best noninvasive marker for monitoring regression? Clin Infect Dis 2020; 73: 468–477. Search in Google Scholar

12 Terrault NA, Pageaux GP. A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! J Hepatol 2018; 69: 767-768. Search in Google Scholar

13 Gavril OI, Arhire LI, Gavrilescu O, Dranga M, Barboi O, Gavril RS, Popescu R, Cijevschi Prelipcean C, Trifan AV, Mihai C. Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response. Medicina (Kaunas). 2021 Oct 24;57(11):1153. Search in Google Scholar

14 Gavril OI, Arhire LI, Gavril RS, Zota MI, Gherasim A, Nita O, Drugescu A, Oprescu AC, Esanu IM, Mitu F, Graur M, Mihalache L. Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients. Medicina (Kaunas). 2021 Nov 15;57(11):1249 Search in Google Scholar

15 Razavi H, Robbins S, Zeuzem S et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 325–336. Search in Google Scholar

16 Singer AW, Reddy KR, Telep LE et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018; 47: 1278–1287. Search in Google Scholar

17 Singh S, Facciorusso A, Loomba R et al. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 27–38. Search in Google Scholar

18 Tamaki N, Kurosaki M, Higuchi M, et al. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS One 2015; 10: e0137351. Search in Google Scholar

19 Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016; 1(169): 101-109. Search in Google Scholar

20 Zoulim F, Liang TJ, Gerbes AL et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64(11): 1824–1833. Search in Google Scholar